Key result
Novel LDL apheresis device Rheocarna undergoes effectiveness appraisal in hemodialysis patients with chronic limb-threatening ischemia.
Critical appraisal examines outcomes of Rheocarna LDL apheresis in hemodialysis patients with limb ischemia, highlighting the need for robust verification.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Zahra et al. (2026) studied this question. The novel low-density lipoprotein apheresis device Rheocarna was critically appraised regarding its effectiveness in hemodialysis patients with chronic limb-threatening ischemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: